Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CCR2 | P41597 | 3/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7722877 | 0.97 | MEN1 (0.32) | MAPTMEN1KMT2AGAA | |
| SCHEMBL7722879 | 0.97 | MEN1 (0.32) | MAPTMEN1KMT2AGAA | |
| SCHEMBL12624596 | 0.96 | CYP2C9 (0.34) | CYP2C9MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL17552976 | 0.94 | MEN1 (0.30) | MEN1KMT2A | |
| SCHEMBL7730846 | 0.93 | CYP1A2 (0.30) | — | |
| SCHEMBL7730842 | 0.93 | CYP1A2 (0.30) | — | |
| SCHEMBL12626546 | 0.93 | OPRL1 (0.33) | — | |
| SCHEMBL16257997 | 0.93 | CYP2C9 (0.33) | CYP2C9MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL12625827 | 0.91 | MEN1 (0.31) | MAPTMEN1KMT2AGAA | |
| SCHEMBL16258079 | 0.91 | MEN1 (0.31) | MAPTMEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951433-B2 | Five-ring liquid crystal compound having CF2O bonding group, liquid crystal composition, and liquid crystal display device | CHISSO CORPORATION (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20100127211-A1 | FIVE-RING LIQUID CRYSTAL COMPOUND HAVING CF20 BONDING GROUP, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100127211-A1 | FIVE-RING LIQUID CRYSTAL COMPOUND HAVING CF20 BONDING GROUP, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CFAP20, KIF20A, KIF20B | CYP2C9 827/4885MAPT 864/4885MEN1 3442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.